NanoCarrier Co., Ltd. (4571.T)
JPY 129.0
(-4.44%)
JPY 129.0
(-4.44%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 1.1 Billion JPY | 0.0% |
| 2022 | 1.1 Billion JPY | -3.57% |
| 2021 | 1.15 Billion JPY | 0.0% |
| 2020 | - JPY | 0.0% |
| 2019 | - JPY | -100.0% |
| 2018 | 2.47 Billion JPY | 0.0% |
| 2017 | 2.47 Billion JPY | 0.0% |
| 2016 | 2.47 Billion JPY | -17.5% |
| 2015 | 3 Billion JPY | 0.0% |
| 2014 | - JPY | -100.0% |
| 2013 | 540 Million JPY | -48.08% |
| 2012 | 1.04 Billion JPY | -38.82% |
| 2011 | 1.7 Billion JPY | 0.0% |
| 2010 | - JPY | 0.0% |
| 2009 | - JPY | 0.0% |
| 2008 | - JPY | 0.0% |
| 2007 | - JPY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 1.1 Billion JPY | -0.08% |
| 2023 Q3 | 1.1 Billion JPY | 0.0% |
| 2023 FY | 1.1 Billion JPY | 0.0% |
| 2023 Q4 | 1.1 Billion JPY | 0.0% |
| 2023 Q1 | 1.1 Billion JPY | 0.0% |
| 2023 Q2 | 1.1 Billion JPY | 0.0% |
| 2022 Q4 | 1.1 Billion JPY | -3.57% |
| 2022 Q3 | 1.15 Billion JPY | 0.0% |
| 2022 FY | 1.1 Billion JPY | -3.57% |
| 2022 Q1 | 1.15 Billion JPY | 0.0% |
| 2022 Q2 | 1.15 Billion JPY | 0.0% |
| 2021 Q2 | 1.15 Billion JPY | 0.0% |
| 2021 Q4 | 1.15 Billion JPY | 0.0% |
| 2021 FY | 1.15 Billion JPY | 0.0% |
| 2021 Q1 | 1.15 Billion JPY | 0.0% |
| 2021 Q3 | 1.15 Billion JPY | 0.0% |
| 2020 FY | - JPY | 0.0% |
| 2020 Q1 | - JPY | 0.0% |
| 2020 Q2 | - JPY | 0.0% |
| 2020 Q3 | - JPY | 0.0% |
| 2020 Q4 | - JPY | 0.0% |
| 2019 Q1 | 527.62 Million JPY | -78.68% |
| 2019 Q3 | - JPY | 0.0% |
| 2019 Q4 | - JPY | 0.0% |
| 2019 FY | - JPY | -100.0% |
| 2019 Q2 | - JPY | -100.0% |
| 2018 Q1 | 2.47 Billion JPY | 0.0% |
| 2018 Q3 | 2.47 Billion JPY | 0.0% |
| 2018 Q4 | 2.47 Billion JPY | 0.0% |
| 2018 FY | 2.47 Billion JPY | 0.0% |
| 2018 Q2 | 2.47 Billion JPY | 0.0% |
| 2017 Q2 | 2.47 Billion JPY | 0.0% |
| 2017 Q4 | 2.47 Billion JPY | 0.0% |
| 2017 FY | 2.47 Billion JPY | 0.0% |
| 2017 Q1 | 2.47 Billion JPY | 0.0% |
| 2017 Q3 | 2.47 Billion JPY | 0.0% |
| 2016 Q3 | 2.47 Billion JPY | 0.0% |
| 2016 FY | 2.47 Billion JPY | -17.5% |
| 2016 Q1 | 2.47 Billion JPY | -17.5% |
| 2016 Q4 | 2.47 Billion JPY | 0.0% |
| 2016 Q2 | 2.47 Billion JPY | 0.0% |
| 2015 Q2 | - JPY | 0.0% |
| 2015 Q1 | - JPY | 0.0% |
| 2015 FY | 3 Billion JPY | 0.0% |
| 2015 Q3 | 3 Billion JPY | 0.0% |
| 2015 Q4 | 3 Billion JPY | 0.0% |
| 2014 Q4 | - JPY | -100.0% |
| 2014 Q3 | 540 Million JPY | 0.0% |
| 2014 FY | - JPY | -100.0% |
| 2014 Q1 | 540 Million JPY | 0.0% |
| 2014 Q2 | 540 Million JPY | 0.0% |
| 2013 Q1 | 1.04 Billion JPY | 0.0% |
| 2013 FY | 540 Million JPY | -48.08% |
| 2013 Q2 | 540 Million JPY | -48.08% |
| 2013 Q3 | 540 Million JPY | 0.0% |
| 2013 Q4 | 540 Million JPY | 0.0% |
| 2012 FY | 1.04 Billion JPY | -38.82% |
| 2012 Q1 | 1.7 Billion JPY | 0.0% |
| 2012 Q2 | 1.7 Billion JPY | 0.0% |
| 2012 Q3 | 1.7 Billion JPY | 0.0% |
| 2012 Q4 | 1.04 Billion JPY | -38.82% |
| 2011 Q4 | 1.7 Billion JPY | 0.0% |
| 2011 Q3 | - JPY | 0.0% |
| 2011 Q1 | - JPY | 0.0% |
| 2011 FY | 1.7 Billion JPY | 0.0% |
| 2011 Q2 | - JPY | 0.0% |
| 2010 Q2 | - JPY | 0.0% |
| 2010 Q3 | - JPY | 0.0% |
| 2010 Q4 | - JPY | 0.0% |
| 2010 Q1 | - JPY | 0.0% |
| 2010 FY | - JPY | 0.0% |
| 2009 FY | - JPY | 0.0% |
| 2009 Q3 | - JPY | 0.0% |
| 2009 Q4 | - JPY | 0.0% |
| 2008 Q3 | - JPY | 0.0% |
| 2008 FY | - JPY | 0.0% |
| 2008 Q4 | - JPY | 0.0% |
| 2007 FY | - JPY | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 2.46 Billion JPY | 55.099% |
| PRISM BioLab Co.,LTD | - JPY | -Infinity% |
| GNI Group Ltd. | 3.69 Billion JPY | 70.025% |
| Linical Co., Ltd. | 3 Billion JPY | 63.06% |
| Trans Genic Inc. | 2.25 Billion JPY | 50.869% |
| MEDINET Co., Ltd. | 2.3 Million JPY | -47967.447% |
| Soiken Holdings Inc. | - JPY | -Infinity% |
| Cytori Cell Research Institute, Inc. | 2.47 Billion JPY | 55.137% |
| AnGes, Inc. | 362.67 Million JPY | -205.76% |
| OncoTherapy Science, Inc. | 106.84 Million JPY | -937.835% |
| Nxera Pharma Co., Ltd. | 73.97 Billion JPY | 98.501% |
| Immuno-Biological Laboratories Co., Ltd. | 235.98 Million JPY | -369.916% |
| Carna Biosciences, Inc. | 182.97 Million JPY | -506.061% |
| CanBas Co., Ltd. | - JPY | -Infinity% |
| D. Western Therapeutics Institute, Inc. | 885.12 Million JPY | -25.284% |
| RaQualia Pharma Inc. | 367.71 Million JPY | -201.567% |
| Chiome Bioscience Inc. | 291 Million JPY | -281.071% |
| Kidswell Bio Corporation | 2.57 Billion JPY | 56.935% |
| PeptiDream Inc. | 22.79 Billion JPY | 95.136% |
| Oncolys BioPharma Inc. | 315.17 Million JPY | -251.847% |
| Ribomic Inc. | - JPY | -Infinity% |
| SanBio Company Limited | 665 Million JPY | -66.754% |
| Healios K.K. | 4.53 Billion JPY | 75.531% |
| BrightPath Biotherapeutics Co., Ltd. | 112.5 Million JPY | -885.703% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 142.85 Million JPY | -676.264% |
| Delta-Fly Pharma, Inc. | - JPY | -Infinity% |
| StemRIM | - JPY | -Infinity% |
| CellSource Co., Ltd. | 97.54 Million JPY | -1036.86% |
| FunPep Company Limited | - JPY | -Infinity% |
| Kringle Pharma, Inc. | - JPY | -Infinity% |
| Stella Pharma Corporation | 933.3 Million JPY | -18.817% |
| TMS Co., Ltd. | - JPY | -Infinity% |
| Noile-Immune Biotech Inc. | - JPY | -Infinity% |
| Cuorips Inc. | - JPY | -Infinity% |
| K Pharma,Inc. | - JPY | -Infinity% |
| Takara Bio Inc. | 968 Million JPY | -14.557% |
| ReproCELL Incorporated | - JPY | -Infinity% |
| PhoenixBio Co., Ltd. | 723.93 Million JPY | -53.18% |
| StemCell Institute Inc. | 8.78 Million JPY | -12524.271% |
| Japan Tissue Engineering Co., Ltd. | - JPY | -Infinity% |
| CellSeed Inc. | 151.25 Million JPY | -633.168% |